Introduction

1. 209 Tumourrecurrence and intravesicalBCG significantly impact upon health related quality of life in patients undergoing conservative management for superficial bladder cancer Nikhil Sapre, Addie C. Wootten, Heather M. Siddons, Anthony J. Costello, Christopher M. Hovens, Niall M. Corcoran and Paul Anderson Departments of Urology and Surgery, Royal Melbourne Hospital and University of Melbourne, Parkville, VIC, Australia Posters Proudly Supported by: Results 64 patients (50M, 14F) completed the questionnaires as a part of a longitudinal study . 20 (31%) patients had recurrent disease and 10 (16%) had previous intravesical BCG treatment. Clinical characteristics of patients are summarised in Table 1. Overall HRQOL outcomes were good with the majority of the people reporting reasonably good HRQOL across the domains of physical, social, emotional, functional and sexual outcomes. Outcomes of patients with and without previous intravesical therapy are shown in Table 2. Patients with previous intravesical BCG treatment had significantly worse urinary symptom scores including daytime frequency (2.7 vs. 1.9 p=0.02), nocturnal frequency (2.67 vs. 1.89 p=0.04) as well as dysuria (2.0 vs. 1.4 p=0.03). Previous BCG however did not have any significant effect on sexual function or bowel symptoms. Outcomes of patients with and without previous disease recurrence are shown in Table 3. People with disease recurrence were coping with their illness significantly worse than people without recurrence (2.9 vs. 2.2 p=0.03) and were also more likely to be worried about deterioration of their disease although this did not reach statistical significance (1.7 vs. 1.1 p=0.09). There was however no difference between the two groups in the overall emotional functioning subscale. People who had recurrent disease and multiple transurethral resections of bladder tumour (TURBT) were also less satisfied with their sexual functioning (2.4 vs. 1.4 p=0.03). The majority of patients reported to have excellent social supports and functional status. Introduction Whilst the health related quality of life (HRQOL) outcomes of patients undergoing cystectomy and urinary diversion have previously been well documented, few have reported outcomes of patients undergoing long-term surveillance for non muscle invasive bladder cancer (NMIBC). Aim The objective of this study was to assess the HRQOL in patients undergoing surveillance for (NMIBC). Table 1: Clinical characteristics of patients in the study Methods We prospectively measured HRQOL outcomes in 64 patients with NMIBC when they presented for their routine surveillance cystoscopy, using a self-reported survey. We used two validated bladder cancer specific quality of life measures to assess outcomes; the European Organization for Research and Treatment of Cancer (EORTC) Superficial Bladder Cancer module and the Functional Assessment of Cancer Therapy for Bladder Cancer (FACT-Bl). Outcomes were measured on a scale of 0 (Not at all) – 4 (Very Much). Clinical outcomes of patients including disease recurrence and progression, previous intravesical BCG therapy and TNM stage/grade were identified from a prospectively recorded and maintained bladder cancer database. Statistical analysis was done using Mann-Whitney U test in SPSS Statistics 19.0 (NY, USA). Table 2: HRQOL outcomes in patients with and without previous intravesical BCG treatment . Conclusions Whilst the overall HRQOL of NMIBC patients undergoing surveillance was reasonably good, having recurrent disease and previous intravesical BCG were associated with significantly worse perception of quality of life. Patients with previous intravesical BCG therapy had more significant urinary symptoms and those with previous disease recurrence had a trend towards increased anxiety over the course of their disease. Table 3: HRQOL outcomes in patients with and without previous disease recurrence Acknowledgements Dr Nikhil Sapre is supported by postgraduate research scholarships from the Royal Australasian College of Surgeons, Cancer Council Victoria and the Cybec Foundation